...
首页> 外文期刊>Translational psychiatry. >Differential effect of quetiapine and lithium on functional connectivity of the striatum in first episode mania
【24h】

Differential effect of quetiapine and lithium on functional connectivity of the striatum in first episode mania

机译:喹硫平和锂对首发躁狂症纹状体功能连接的差异作用

获取原文

摘要

Mood disturbances seen in first-episode mania (FEM) are linked to disturbed functional connectivity of the striatum. Lithium and quetiapine are effective treatments for mania but their neurobiological effects remain largely unknown. We conducted a single-blinded randomized controlled maintenance trial in 61 FEM patients and 30 healthy controls. Patients were stabilized for a minimum of 2 weeks on lithium plus quetiapine then randomly assigned to either lithium (serum level 0.6?mmol/L) or quetiapine (dosed up to 800?mg/day) treatment for 12 months. Resting-state fMRI was acquired at baseline, 3 months (patient only) and 12 months. The effects of treatment group, time and their interaction, on striatal functional connectivity were assessed using voxel-wise general linear modelling. At baseline, FEM patients showed reduced connectivity in the dorsal ( p =?0.05) and caudal ( p =?0.008) cortico-striatal systems when compared to healthy controls at baseline. FEM patients also showed increased connectivity in a circuit linking the ventral striatum with the medial orbitofrontal cortex, cerebellum and thalamus ( p =?0.02). Longitudinally, we found a significant interaction between time and treatment group, such that lithium was more rapid, compared to quetiapine, in normalizing abnormally increased functional connectivity, as assessed at 3-month and 12-month follow-ups. The results suggest that FEM is associated with reduced connectivity in dorsal and caudal corticostriatal systems, as well as increased functional connectivity of ventral striatal systems. Lithium appears to act more rapidly than quetiapine in normalizing hyperconnectivity of the ventral striatum with the cerebellum. The study was registered on the Australian and New Zealand Clinical Trials Registry (ACTRN12607000639426). http://www.anzctr.org.au.
机译:在首发躁狂症(FEM)中出现的情绪障碍与纹状体功能障碍有关。锂和喹硫平是治疗躁狂症的有效方法,但是它们的神经生物学作用仍然未知。我们对61名FEM患者和30名健康对照进行了单盲随机对照维持试验。用锂加喹硫平将患者稳定至少2周,然后随机分配锂(血清水平为0.6?mmol / L)或喹硫平(剂量为800?mg /天)治疗12个月。在基线,3个月(仅患者)和12个月时获得了静止状态fMRI。使用体素常规线性模型评估治疗组,时间及其相互作用对纹状体功能连接的影响。在基线时,与基线时的健康对照组相比,FEM患者在背侧(p = 0.05)和尾侧(p = 0.008)皮质-纹状体系统中的连通性降低。 FEM患者还显示出连接腹侧纹状体与内侧眶额皮质,小脑和丘脑的回路中的连通性增加(p =?0.02)。纵向上,我们发现时间和治疗组之间存在显着的相互作用,因此,与喹硫平相比,锂能够更快地恢复异常增加的功能连通性,如在3个月和12个月的随访中所评估的。结果表明,有限元法与背侧和尾部皮层皮质系统的连通性降低以及腹侧纹状体系统的功能连通性增加有关。在使腹侧纹状体与小脑的过度连接正常化方面,锂的作用似乎比喹硫平更快。该研究已在澳大利亚和新西兰临床试验注册中心(ACTRN12607000639426)注册。 http://www.anzctr.org.au。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号